FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists), Flt3L stimulants(Fms-related tyrosine kinase 3 ligand stimulants)

Therapeutic Areas

NeoplasmsUrogenital DiseasesOther Diseases+ [4]

Active Indication

Metastatic Renal Cell CarcinomaSoft Tissue NeoplasmsSarcoma+ [11]

Inactive Indication

Adenocarcinoma of prostateAdvanced breast cancerAdvanced gastric carcinoma+ [140]

Originator Organization

GSK Plc

Active Organization

Novartis Pharmaceuticals Corp.

Novartis AGNovartis Europharm Ltd.

+ [4]

Inactive Organization

GlaxoSmithKline (China) R&D Co., Ltd.

GlaxoSmithKline (China) Investment Co., Ltd.

Glaxo Group Ltd.

+ [9]

License Organization

Qingdao Baheal Medical, Inc.

Novartis AG

Beijing Novartis Pharma Co. Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (19 Oct 2009),

Advanced Renal Cell Carcinoma

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC21H24ClN7O2S

InChIKeyMQHIQUBXFFAOMK-UHFFFAOYSA-N

CAS Registry635702-64-6

330

Clinical Trials associated with Pazopanib Hydrochloride

ACTRN12625000814471

/ RecruitingPhase 1IIT

An investigation of the impact of concomitant green tea consumption on the pharmacokinetics of a single dose of pazopanib in healthy participants.

Start Date20 Aug 2025

Sponsor / Collaborator

The University of Sydney

NCT07087158

/ Not yet recruitingPhase 2

A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.

Start Date10 Aug 2025

Sponsor / Collaborator

Imbioray (Hangzhou) Biomedicine Co., Ltd.

NCT04199026

/ RecruitingNot ApplicableIIT

Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas

This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.

Start Date25 Feb 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Pazopanib Hydrochloride

100 Translational Medicine associated with Pazopanib Hydrochloride

100 Patents (Medical) associated with Pazopanib Hydrochloride

2,992

Literatures (Medical) associated with Pazopanib Hydrochloride

01 Apr 2026·DRUG DEVELOPMENT RESEARCH

From Cancer to Neuroprotection: Pazopanib Modulates the RIPK1/RIPK3/MLKL and PGAM5/DRP1 Pathways in 3‐ Nitropropionic Acid‐Induced Huntington's Disease

Article

Author: Sayed, Rabab H. ; Eltarzy, Muhammad A. ; Ahmedy, Omaima A. ; Rabie, Mostafa A. ; Ahmed, Maha A. E.

ABSTRACT:

Huntington's disease (HD) is a progressive neurodegenerative disorder with a poorly understood neurobiological basis. Among the various forms of programmed cell death implicated in neurodegeneration, necroptosis has recently garnered significant attention. Notably, dysregulated necroptosis provokes immune response that drives excessive pro‐inflammatory cytokine production, promoting further necroptotic cell death through TNF‐α/RIPK1 signaling. Consequently, necroptosis exacerbates neuroinflammation, contributing to the progression of different neurodegenerative diseases. However, the precise role of necroptosis in HD pathogenesis remains unclear. Given the growing interest in repurposing FDA‐approved drugs for novel therapeutic interventions, this study investigates the anti‐cancer agent Pazopanib (Pazo) as a potential neuroprotective approach for HD. This study assesses Pazo's ability to mitigate necroptosis by targeting the RIPK1/RIPK3/MLKL pathway in a model of HD produced by 3‐nitropropionic acid (3‐NP). Sixty male Wistar rats were randomly assigned to four groups: Group I received normal saline; Group II received Pazo (15 mg/kg, i.p.); Group III received 3‐NP (10 mg/kg, i.p.); and Group IV received 3‐NP (10 mg/kg, i.p.) and Pazo (15 mg/kg, i.p.). Behavioral assessments, including open field, rotarod, and wire hanging tests, demonstrated that Pazo significantly improved motor function. At the molecular level, Pazo inhibited PGAM5, a key regulator of mitochondrial fission, effectively reversing the RIPK1/RIPK3/MLKL necroptotic cascade and the consequent immune activation. This suppression of necroptosis was associated with reduced microgliosis, neuroinflammation and enhanced neuronal survival within the striatum. These findings highlight the potential of Pazo as a neuroprotective agent against HD by leveraging its antioxidant, anti‐inflammatory, immune‐modulating, and anti‐necroptotic properties.

01 Mar 2026·BIOMEDICAL CHROMATOGRAPHY

An LC–MS/MS‐Based Quantification of Intracellular Anlotinib Reveals Exposure–Toxicity Relationships in Endothelial and Intestinal Epithelial Cells

Article

Author: Li, Huanchen ; Jiang, Zhenhui ; Ye, Liya ; Xu, Jingjie ; Tao, Xia ; Liu, Zhijun ; Wang, Zhipeng ; Sun, Jianguo ; Gao, Shouhong

ABSTRACT:

Local drug exposure is closely associated with both therapeutic efficacy and adverse reactions. Anlotinib is approved for the treatment of chemotherapy‐refractory or metastatic non‐small cell lung cancer; its clinical application is limited by severe adverse reactions, particularly hypertension and diarrhea, and the relationship between intracellular exposure and toxicity remains unclear. In this study, a rapid and sensitive UHPLC–MS/MS method was developed using an Agilent 1290‐6460A ultra‐high performance liquid chromatography coupled to a triple quadrupole mass spectrometer to quantify anlotinib in human intestinal epithelial cells (HIECs) and human umbilical vein endothelial cells (HUVECs). Pazopanib‐d3 was employed as an internal standard, and anlotinib was accurately quantified in 10–4000 ng/mL in positive ionization mode, with acceptable specificity, linearity, accuracy, precision, stability, and dilution integrity. The method was successfully applied to determine intracellular and extracellular anlotinib concentrations in HIECs and HUVECs. Notably, significant differences were observed between intracellular and extracellular concentrations, and intracellular anlotinib concentrations, rather than extracellular concentrations, were positively correlated with cytotoxicity in both cell types. Collectively, this study established a robust analytical approach for intracellular anlotinib quantification and provided experimental evidence linking intracellular exposure to cytotoxicity, offering a foundation for further investigation of anlotinib‐induced adverse reactions.

01 Feb 2026·CURRENT OPINION IN PEDIATRICS

Update on pediatric soft tissue sarcomas

Review

Author: Crane, Jacquelyn ; Aye, Jamie ; Oberoi, Sapna

Purpose of review:

The purpose of this review is to highlight recent findings in the diagnosis, biology, risk-stratification, and treatment of soft tissue sarcomas (STS) in children.

Recent findings:

In rhabdomyosarcoma (RMS), FOXO1 fusion status has been confirmed as an important prognostic factor. Among fusion-negative RMS, TP53 and MYOD1 mutations and detectable circulating tumor DNA at diagnosis are associated with inferior event-free survival in intermediate-risk disease. Delayed primary excision is associated with a reduced risk of local failure whereas radiotherapy dose escalation in large tumors has not improved local control. Maintenance therapy with vinorelbine and oral cyclophosphamide following induction chemotherapy in the RMS2005 trial led to improved survival. In non-rhabdomyosarcoma soft tissue sarcomas, the addition of pazopanib, a multitargeted receptor tyrosine kinase inhibitor, to upfront therapy did not improve survival. Atezolizumab is approved for alveolar soft part sarcoma, larotrectinib for NTRK fusion–positive STS, and afamitresgene autoleucel remains under evaluation in children with synovial sarcoma. Encouraging early results have been reported with tazemetostat and immune checkpoint inhibitors in epithelioid sarcoma and trastuzumab in desmoplastic small round cell tumor, respectively.

Summary:

Pediatric STS are rare and biologically heterogeneous. Genomic advances have refined risk stratification and uncovered therapeutic targets; further progress relies on international collaboration and trials.

News (Medical) associated with Pazopanib Hydrochloride

27 Oct 2025

·www.drugs.com

Pazopanib Well-Tolerated in Young With Primary Multimetastatic Ewing Sarcoma

MONDAY, Oct. 27, 2025 -- For young patients with primary multimetastatic Ewing sarcoma, pazopanib is well-tolerated and effective, according to a study published online Oct. 22 in Frontiers in Oncology . Noting that pazopanib has been proposed as an effective salvage regimen for soft tissue sarcoma, including extraosseous Ewing sarcoma, Anna Raciborska, M.D., Ph.D., from the Institute of Mother and Child in Warsaw, Poland, and colleagues examined this approach for young patients with primary multimetastatic bone Ewing sarcoma. Eleven patients received standard first-line treatment in parallel with pazopanib. The researchers found that pazopanib was administered for an average of 1.7 years, throughout the treatment period and after its completion (paused during the surgical procedure). Patients' median age was 14.2 years at the beginning of pazopanib treatment. Five patients underwent surgery on the primary tumor; 10 received concurrent radiation therapy and three underwent autologous hematopoietic stem cell transplantation. No significant toxicities were observed. One, two, and one patients progressed, had relapse, and died (9.1, 18.2, and 9.1 percent, respectively). With a median follow-up of 2.6 years, 10 patients (90.9 percent) were alive. For the whole group, estimated two-year event-free and overall survival were 68.2 and 85.7 percent, respectively. "Survival rates were higher than in historical controls, suggesting it may extend lives and, importantly, do so without adding severe toxicity," Raciborska said in a statement. "Moreover, the quality of life of treated children was good." Abstract/Full Text

Clinical ResultRadiation Therapy

23 Oct 2025

·www.drugs.com

Votrient Might Extend Survival Among Kids With Rare Bone Cancer

THURSDAY, Oct. 23, 2025 — Kids with a rare bone cancer might live longer if prescribed a drug that blocks blood supply to tumors, researchers say. The drug pazopanib ( Votrient ) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors in their bones, researchers report in the journal Frontiers in Oncology . “While we wait for new treatment options, it is possible to implement this existing drug to improve outcomes in very high-risk patients,” lead researcher Anna Raciborska , head of oncology at Poland’s Warsaw Mother and Child Institute, said in a news release. “It opens the door to targeted therapies earlier in the disease course, potentially improving survival and quality of life.” Typically, fewer than a quarter of children with advanced Ewing sarcoma survive five years after their diagnosis, researchers said in background notes. But the research team thought that pazopanib, which was initially developed for kidney cancer, might also be effective in staving off Ewing sarcoma. “Pazopanib is a pill that blocks the tumor's ability to grow new blood vessels, which tumors need to survive and spread,” Raciborska said. “By cutting off this ‘blood supply,’ the drug presumably makes tumors weaker and more sensitive to chemotherapy and radiation. This may slow down the disease and help existing treatments work better.” Between 2016 and 2024, 11 children ages 5 to 18 were given pazopanib alongside the standard treatments for their cancer, which can include chemo, surgery, radiation therapy or stem cell transplants. About 86% of the children survived two years after their diagnosis, results showed. Further, two-thirds (68%) saw no progression in their cancer, researchers said. At this point, 10 of the children are still alive, and six are still taking pazopanib, researchers said. One child’s cancer has progressed, and two have suffered a relapse. Pazopanib also produced minimal side effects, researchers said. More research is needed to validate these results, the authors said, but advanced Ewing sarcoma is so rare that it can be difficult to recruit enough patients for larger clinical trials. “While the results are encouraging, larger controlled trials are needed before changing standard practice,” Raciborska said. “Our study could serve as a basis for creating prospective, multicenter clinical trials to confirm these promising results. However, this requires a lot of work and the commitment of resources.” Sources Frontiers, news release, Oct. 23, 2025

Radiation TherapyClinical ResultClinical Study

20 Aug 2025

·www.prnewswire.com

HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight

The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma, representing a potential expansion into solid tumors. Quisinostat (Viriom) is in Phase II for uveal melanoma, and Entinostat, partnered between EOC Pharma and Syndax, is being explored in Hodgkin lymphoma. LAS VEGAS, Aug. 20, 2025 /PRNewswire/ -- DelveInsight's HDAC Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Multiple Myeloma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Amyotrophic Lateral Sclerosis (ALS), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging HDAC inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the HDAC Inhibitors Market Report As per DelveInsight's analysis, the total market size of HDAC inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Multiple Myeloma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Amyotrophic Lateral Sclerosis (ALS), and others. Leading HDAC inhibitor companies, such as Xynomic Pharmaceuticals, Viriom, EOC Pharma, Syndax Pharmaceuticals, Jubilant Therapeutics, and others, are developing novel HDAC inhibitors that can be available in the HDAC inhibitors market in the coming years. Some of the key HDAC inhibitors in the pipeline include Abexinostat, Quisinostat, Entinostat, JBI-802, and others. Discover which indication is expected to grab the major HDAC inhibitors market share @ HDAC Inhibitors Market Report HDAC Inhibitors Overview Histone deacetylases (HDACs) remove acetyl groups from both histone and non-histone proteins. Because acetylation of histones is linked to an open chromatin structure and active gene transcription, HDAC activity leads to histone deacetylation and epigenetic suppression of gene expression. Since HDACs influence many pathways involved in cancer development, HDAC inhibitors (HDACis) show clinical effects through several mechanisms, including changes in gene expression of cell cycle and apoptotic proteins, acetylation of other proteins involved in cell growth and survival, effects on angiogenesis, aggresome formation, and DNA repair. There are 18 known HDACs, divided into two major groups and four classes based on their cellular location, homology, enzyme mechanism, sequence of discovery, and histone substrate specificity. The first group includes zinc-dependent HDACs, which all share a similar catalytic core for deacetylating acetyl-lysine residues. These comprise Class I (HDAC1, -2, -3, -8), Class II (IIa: HDAC4, -5, -7, -9; IIb: HDAC6, -10), and Class IV (HDAC11). The second group includes Class III HDACs (sirtuins, SIRT1–7), which rely on NAD+ for their enzymatic activity. HDAC Inhibitors Epidemiology Segmentation The HDAC inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for HDAC Inhibitor Total Eligible Patient Pool of Selected Indications for HDAC Inhibitor Total Treated Cases of Selected Indications for HDAC Inhibitor HDAC Inhibitors Treatment Market Several HDAC inhibitors are currently available on the market. Recent entrants include DUVYZAT (givinostat), while earlier approved drugs include BELEODAQ (belinostat), HIYASTA (tucidinostat), among others. DUVYZAT is a histone deacetylase inhibitor approved for treating Duchenne muscular dystrophy (DMD) in patients aged 6 and above. While it is categorized as an HDAC inhibitor, its exact mechanism of action in DMD is not fully understood. In April 2025, Italfarmaco announced that the CHMP of the European Medicines Agency (EMA) issued a positive opinion on DUVYZAT. The drug is also being evaluated in other indications: Phase III trial in Becker muscular dystrophy (BMD) and Phase II trial in polycythemia vera. HIYASTA (HBI-8000) is an epigenetic immunomodulator approved for several indications, including use as monotherapy for certain subtypes of relapsed or refractory T-cell non-Hodgkin's lymphoma, specifically adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL) in Japan. HUYABIO International is conducting a multinational Phase III trial evaluating HIYASTA in combination with nivolumab for previously untreated metastatic or unresectable malignant melanoma. HIYASTA is an oral HDAC Class I inhibitor that induces cell cycle arrest and apoptosis in tumor cells, which underlies its efficacy in lymphoma. In September 2020, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation (ODD) to HIYASTA for relapsed/refractory ATL, and in December 2015 for PTCL. In June 2021, HUYABIO also received regulatory approval in Japan for HBI-8000 as monotherapy for relapsed/refractory ATL. Key Emerging HDAC Inhibitors and Companies Xynomic Pharmaceuticals (Abexinostat), Viriom (Quisinostat), EOC Pharma/Syndax Pharmaceuticals (Entinostat), Jubilant Therapeutics (JBI-802), and several other companies are currently engaged in the development and production of HDAC inhibitors, which have the potential to significantly impact and enhance the HDAC inhibitors market. Abexinostat, an oral, broad-spectrum HDAC inhibitor originally developed by Pharmacyclics and later licensed by Xynomic Pharmaceuticals in 2017, has demonstrated encouraging activity in both blood cancers and solid tumors. The drug is currently being studied in several Phase I to III clinical trials worldwide. In September 2019, Xynomic announced that the FDA had granted Fast Track Designation (FTD) to abexinostat as a monotherapy for fourth-line treatment of relapsed or refractory follicular lymphoma. The FDA had previously granted FTD for abexinostat in combination with pazopanib for first- or second-line therapy in renal cell carcinoma. Additional Phase II trials are underway in indications such as Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma. Quisinostat is another potent, selective oral pan-HDAC inhibitor, initially developed by Janssen Pharmaceuticals. HDAC inhibitors work by inducing cell cycle arrest, promoting differentiation, and triggering apoptosis in various human cancer cell lines. By inhibiting histone deacetylase, they increase acetylation of histone proteins, resulting in a more transcriptionally active chromatin state and altered gene expression involved in proliferation, apoptosis, and differentiation. Multiple preclinical studies and Phase I/II trials have evaluated quisinostat's safety and effectiveness, showing promising anti-tumor effects in several advanced and treatment-resistant cancers — including platinum-resistant ovarian cancer (in combination with paclitaxel and carboplatin), uveal melanoma, and synovial sarcoma. The anticipated launch of these emerging therapies are poised to transform the HDAC inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HDAC inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HDAC inhibitors clinical trials, visit @ HDAC Inhibitors Treatment Recent Developments in the HDAC Inhibitors Space In May 2025, Amylyx Pharmaceuticals announced positive Week 48 data from the Phase II open-label HELIOS clinical trial of AMX0035 in adults living with Wolfram syndrome. In May 2025, the University of Miami, in collaboration with Viriom, initiated a Phase II clinical trial in the US (NCT06932757) to evaluate an oral therapy for patients with uveal melanoma who have undergone at least one prior line of treatment. In April 2025, Xynomic Pharmaceuticals concluded a Phase I/II clinical trial in the United States (NCT03939182), evaluating a combination oral therapy for patients with Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma who had received at least one prior line of treatment. Discover more about HDAC inhibitors in development @ HDAC Inhibitors Clinical Trials HDAC Inhibitors Market Dynamics HDAC inhibitors are a class of epigenetic drugs that modify gene expression by altering chromatin structure. Initially developed as anticancer agents, they have shown significant therapeutic potential in various malignancies, especially hematologic cancers like T-cell lymphoma and multiple myeloma. The market initially gained traction with FDA approvals of drugs such as Vorinostat, Romidepsin, and Panobinostat. Their unique mechanism of action targeting epigenetic regulation drew interest as precision medicine and oncology research grew, driving pharmaceutical investment in this segment. The HDAC inhibitors market continues to expand largely due to the rising prevalence of cancer worldwide and the need for more targeted therapies with better safety profiles. Additionally, ongoing clinical trials are exploring HDAC inhibitors in combination with other therapies, such as immune checkpoint inhibitors, proteasome inhibitors, and traditional chemotherapeutics. These combination approaches aim to overcome resistance and enhance efficacy, creating more opportunities for market growth. As more data emerges demonstrating synergistic benefits, partnerships between biotech startups and large pharmaceutical firms are accelerating further development. Despite this positive outlook, the market faces several challenges. Many HDAC inhibitors are associated with toxicity issues such as fatigue, gastrointestinal disturbances, and thrombocytopenia, which limit broader adoption. Competition from newer targeted therapies and immuno-oncology drugs also puts pressure on the HDAC inhibitor segment. Moreover, several compounds failed in late-stage trials due to a lack of efficacy, leading to cautious investor sentiment and prioritization of combination rather than monotherapy approaches. Looking ahead, the market dynamics are expected to be shaped increasingly by precision oncology trends and biomarker-driven patient selection, allowing more effective targeting of responders. If safety profiles can be improved and combination regimens continue to show strong results, HDAC inhibitors will retain a meaningful role in the evolving oncology landscape. Novel formulations, selective HDAC isoform inhibitors, and expansion into non-oncology indications such as neurodegenerative or inflammatory diseases may further diversify the market and drive its next phase of growth. Learn more about the HDAC inhibitors @ HDAC Inhibitors Analysis Scope of the HDAC Inhibitors Market Report HDAC Inhibitors Therapeutic Assessment: HDAC Inhibitors' current marketed and emerging therapies HDAC Inhibitors Market Dynamics: Conjoint Analysis of Emerging HDAC Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, HDAC Inhibitors Market Access and Reimbursement Table of Contents Related Reports Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others. Amyotrophic Lateral Sclerosis Market Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALS companies, including AB Science, Alector, GSK, Brainstorm Cell Therapeutics, Ionis Pharmaceuticals, Medicinova, Denali Therapeutics, AbbVie, Calico Life Sciences, Clene Nanomedicine Biosciences, Seelos Therapeutics, Prilenia Therapeutics, Rapa Therapeutics, Neurosense Therapeutics, Helixmith, Transposon Therapeutics, Revalesio Corporation, Annexon Biosciences, Corcept Therapeutics, AL-S Pharma, Sanofi, Denali Therapeutics, Orphai Therapeutics, among others. Peripheral T-cell Lymphoma Market Peripheral T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others. Cutaneous T-cell Lymphoma Market Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Pfizer, Helsinn Therapeutics, Kyowa Hakko Kirin, Citius Pharmaceuticals, Soligenix, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, BioInvent International AB, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 3Fast TrackOrphan DrugImmunotherapy

100 Deals associated with Pazopanib Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D05380	Pazopanib Hydrochloride	L01XE11	DB06589

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic Renal Cell Carcinoma	Japan	Novartis Pharma KK	17 Mar 2014
Soft Tissue Neoplasms	Japan	Novartis Pharma KK	28 Sep 2012
Sarcoma	United States	Novartis Pharmaceuticals Corp.	26 Apr 2012
Renal Cell Carcinoma	European Union	Novartis Europharm Ltd.	14 Jun 2010
Renal Cell Carcinoma	Iceland	Novartis Europharm Ltd.	14 Jun 2010
Renal Cell Carcinoma	Liechtenstein	Novartis Europharm Ltd.	14 Jun 2010
Renal Cell Carcinoma	Norway	Novartis Europharm Ltd.	14 Jun 2010
Soft Tissue Sarcoma	European Union	Novartis Europharm Ltd.	14 Jun 2010
Soft Tissue Sarcoma	Iceland	Novartis Europharm Ltd.	14 Jun 2010
Soft Tissue Sarcoma	Liechtenstein	Novartis Europharm Ltd.	14 Jun 2010
Soft Tissue Sarcoma	Norway	Novartis Europharm Ltd.	14 Jun 2010
Advanced Renal Cell Carcinoma	United States	Novartis Pharmaceuticals Corp.	19 Oct 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	Belgium	GlaxoSmithKline Research & Development Ltd.	15 Feb 2011
Fallopian Tube Carcinoma	Phase 3	Germany	Novartis Pharma Services AG	20 Feb 2009
Ovarian Epithelial Carcinoma	Phase 3	Germany	Novartis Pharma Services AG	20 Feb 2009
Primary peritoneal carcinoma	Phase 3	Germany	Novartis Pharma Services AG	20 Feb 2009
Inflammatory Breast Neoplasms	Phase 3	Greece	GlaxoSmithKline Research & Development Ltd.	14 Aug 2007
Neoplasms	Phase 3	Greece	GlaxoSmithKline Research & Development Ltd.	14 Aug 2007
Locally Advanced Clear Cell Renal Cell Carcinoma	Phase 3	China	GSK Plc	01 Apr 2006
Locally Advanced Clear Cell Renal Cell Carcinoma	Phase 3	Argentina	GSK Plc	01 Apr 2006
Locally Advanced Clear Cell Renal Cell Carcinoma	Phase 3	Australia	GSK Plc	01 Apr 2006
Locally Advanced Clear Cell Renal Cell Carcinoma	Phase 3	Austria	GSK Plc	01 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2025	Not Applicable	Metastatic Soft Tissue Sarcoma EMMPRIN	88	Pazopanib (Training cohort)	fcjyiohusi(nrzmjytoix) = Low EMMPRIN level was significantly associated with longer overall survival in univariate analysis in training cohort [HR 0.49 (CI95% 0.27-0.89), P = 0.019] but not in validation cohort [HR = 0.69, (CI95% 0.33-1.44), P= 0.3] zcdxhqhrxw (rdzkvwkptr ) View more	Positive	17 Oct 2025
				Pazopanib (Validation cohort)
NCT01841736 (A021202, Pubmed \| J Clin Oncol)	Phase 2	Advanced Pancreatic Neuroendocrine Tumor	171	Pazopanib 800 mg once daily	vhifpevslb(ggmruwsvom) = pwwtthywoh qeolrbxggm (isushpfajw ) View more	Negative	10 Oct 2025
				Placebo	vhifpevslb(ggmruwsvom) = gfpsyjfzcd qeolrbxggm (isushpfajw ) View more
NCT02066285 (GEIS 32, ASCO2025)	Phase 2	Solitary Fibrous Tumors	40	pazopanib (High-risk gene signature group)	kvhnvxjqwc(kfdaajrlia) = mxtvgxpplk ngauqrpxns (xvgczulmnj, 3.7 - 10.0)	Positive	30 May 2025
				pazopanib (Low-risk gene signature group)	kvhnvxjqwc(kfdaajrlia) = etgsusmlaa ngauqrpxns (xvgczulmnj, 6.5 - NR)
NCT01436227 (CTgov)	Phase 2	Von Hippel-Lindau Disease	32	Pazopanib Hydrochloride	bvynjemsjk = hgqdouldfr zmswbxlese (dgdtgcofvy, zhoambcbkp - plnlukigbn) View more	-	02 May 2025
ESMO_SRC2025 \| ESMO2025	Not Applicable	Sarcoma	1,573	Pazopanib	ujfqwzbswt(ecfeevuaqf) = 33% cnfxwkzckt (dlpieynxyh ) View more	Positive	21 Mar 2025
				Other TKIs
NCT01684397 (ESMO2024) Manual	Phase 2	Metastatic Clear Cell Renal Cell Carcinoma First line	51	Pazopanib bevacizumab	pkqabmlsxj(rqkijvqivh) = fowgkluwqe ucgqwaxdqg (yhpiydaszv ) View more	Positive	15 Sep 2024
ISRCTN91273375 \| NCT00866697 \| NCT01015118 (AGO-OVAR 16 \| AGO-OVAR 12 \| AGO-OVAR 11, ESMO2024)	Phase 3	KRAS-mutated low-grade serous ovarian cancer First line	137	Carboplatin/Paclitaxel + Bevacizumab	rishpjfniv(vsxlftvsyk): HR = 0.87, P-Value = 0.88	Negative	14 Sep 2024
				Carboplatin/Paclitaxel + Nintedanib/Placebo
NCT02207309 (CTgov)	Phase 2	Sarcoma \| Retroperitoneal Sarcoma \| Chondrosarcoma, Extraskeletal Myxoid ... View more	1	Pazopanib (Pazopanib)	zipfgctzxr = buwkstaijp ggbpqezlzo (zhkytabcuz, ykiaykewpc - kevsfjfcvr) View more	-	09 Aug 2024
				Placebo (for Pazopanib) (Placebo)	zipfgctzxr = zribsjbvbn ggbpqezlzo (zhkytabcuz, lzgzuhylkm - viebptoadz) View more
NCT03260894 (KEYNOTE-679/ECHO-302, Pubmed) Manual	Phase 3	Metastatic Renal Cell Carcinoma First line	129	Pembrolizumab plus epacadostat	fxtbzqpmrb(vpudqngjwa) = ngnxpenleh kcotdejtqq (jbccipzplv, 20.2 - 44.1) View more	Negative	25 Jul 2024
				Sunitinib or pazopanib	fxtbzqpmrb(vpudqngjwa) = vhceogkctv kcotdejtqq (jbccipzplv, 18.6 - 41.8) View more
ASCO2024 Manual	Not Applicable	Metastatic Renal Cell Carcinoma First line	611	Ipilimumab + NivolumabNivolumab (IPI/NIVO) (Favorable Risk)	ntgjbokzte(bfkqgdcfkj) = utezmugbef nckfnukqcf (zpukyhhvyl, 77.4 - 95.4) View more	-	24 May 2024
				IO-VEGF (Pembrolizumab and Axitinib or Lenvatinib, AvelumabLenvatinib, Avelumab and Axitinib, or Nivolumab and CabozantinibCabozantinib) (Favorable Risk)	ntgjbokzte(bfkqgdcfkj) = nvkxihokix nckfnukqcf (zpukyhhvyl, 77.0 - 91.2) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis